Cariprazine - Gedeon Richter

Drug Profile

Cariprazine - Gedeon Richter

Alternative Names: Cariprazine prolonged release; MP-214; Reagila; RGH-188; RGH-188 HCl; Vraylar

Latest Information Update: 20 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gedeon Richter
  • Developer Allergan; Gedeon Richter; Mitsubishi Tanabe Pharma Corporation; Recordati
  • Class Antidepressants; Antipsychotics; Chlorobenzenes; Cyclohexanes; Piperazines; Small molecules; Urea compounds
  • Mechanism of Action Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists; Serotonin 1A receptor partial agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Schizophrenia
  • Phase III Bipolar depression; Major depressive disorder
  • Phase I Schizoaffective disorder
  • No development reported Mental disorders

Most Recent Events

  • 30 Jul 2018 Phase-III clinical trials in Schizophrenia (In adults) in USA (PO) (NCT03593213)
  • 26 Jul 2018 Forest Laboratories (now Allergan) plans a phase III trial for Schizophrenia in USA , (NCT03593213)
  • 19 Jun 2018 Gedeon Richter completes a phase I trial in Schizoaffective disorder and Schizophrenia (In adolescents) in Bulgaria (PO) (EudraCT2016-002327-29)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top